Tag: Manufacturing

The coronavirus outbreak and the drop in economy that we are facing today is unlike anything that most of us have seen in our lifetime. The pandemic has threatened the whole world to such an extent that life has come to a standstill. In fact, the initial stage of lockdown featured the fragile nature of

Recent developments in pharmacology and biotechnology have been able to drive significant advances and innovation in understanding the root causes of various diseases; this has further aided in the discovery and development of more targeted treatment strategies. It is worth noting that such advances in the healthcare industry have made pharmaceutical development and CMO manufacturing

Over the years, several industries have implemented evolutionary changes in their respective manufacturing processes. One to the most rewarding advancements in this direction, is process automation. In pharmaceutical contract manufacturing, the automation of various aspects of the production process has led to the establishment of the continuous manufacturing system providers. However, the transition to continuous

The concept of modular cleanroom has long been employed in other sectors, but it has only recently acquired traction in the pharmaceutical business over the last two to three decades. Modular cleanroom construction is a process wherein factory-produced, pre-engineered building units, which are constructed offsite under controlled plant conditions, are assembled on site to construct

The recent years have portrayed the renaissance in the domain of biologics, as pharmaceutical industry has once again gained attention towards the production of bioproducts. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapy) were approved in the US. Further, over 8,000 biological pharmaceutical products are

Antibody Drug Conjugates (ADCs) manufacturing known as the 21st Century Magic Bullets, have emerged as a promising class of targeted therapies being developed for the treatment of cancer. Two decades ago, in the year 2000, the domain witnessed the approval of first ADC known as Mylotarg®, by the US FDA.  This was followed by the

The recent years have portrayed the renaissance of peptide therapeutics, as pharma industry has once again turned its attention towards the potential of therapeutic peptides. Adoption of peptide therapeutics agents have side-lined some of the earlier concerns associated with them, such as drug bioavailability enhancement, and has led to manufacturing of high-quality peptide therapeutics in

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic medication development and production operations to contract service providers. Over 240 companies

What is the current development pipeline of microbiome manufacturing based live biotherapeutics? With over 85 products under preclinical and clinical development, the current development pipeline of microbiome manufacturing based live biotherapeutics has several promising candidates, which are anticipated to get commercialized over the next few years. Hence, the demand for R&D and manufacturing services for

Microbiome therapeutics are fragile bacteria, which require ideal conditions of heat, moisture and pH of products, to survive and prevent premature germination. In fact, microbiome manufacturing is presently one of the biggest bottlenecks in this domain; manufacturing such products is both technically challenging and financially demanding. One of the biggest challenges in the development of

The world has experienced a radical change with the advancements in technologies and systems that aid daily activities. Particularly, lab automation has played an important role in increasing the productivity and quality of the production process in various industries. Within the automation industry, robots have already been established; however, one of the fastest-growing segment of

Cell Therapy Manufacturing market has gained significant attention in the overall biopharmaceutical industry. The personalized nature of these cell therapies options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017).